All-cause mortality benefits of attending phase 3 cardiac rehabilitation: A systematic review

IF 2 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Revista Portuguesa De Cardiologia Pub Date : 2026-09-01 Epub Date: 2026-08-05 DOI:10.1016/j.repc.2025.11.014

Inês Aguiar-Ricardo, Daniel Inácio Cazeiro, Pedro Alves da Silva, Catarina Sena Silva, Ana Abrantes, Nelson Cunha, Maria Clarissa Rodrigues, Ana Rita Cardoso Andrade, Rita Pinto, Daniel Caldeira, Fausto J. Pinto, Ana Abreu

{"title":"All-cause mortality benefits of attending phase 3 cardiac rehabilitation: A systematic review","authors":"Inês Aguiar-Ricardo, Daniel Inácio Cazeiro, Pedro Alves da Silva, Catarina Sena Silva, Ana Abrantes, Nelson Cunha, Maria Clarissa Rodrigues, Ana Rita Cardoso Andrade, Rita Pinto, Daniel Caldeira, Fausto J. Pinto, Ana Abreu","doi":"10.1016/j.repc.2025.11.014","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><div>The primary objective of this study was to assess the impact of attending a phase 3 cardiac rehabilitation (CR) program on all-cause mortality.</div></div><div><h3>Methods</h3><div>We conducted a systematic review using database searches (MEDLINE and Cochrane Central Register of Controlled Trials) up to December 2022 to identify studies that compared adult patients undergoing phase 3 of CR with those receiving usual care.</div></div><div><h3>Results</h3><div>Out of a total of 1867 identified articles, eight met the eligibility criteria (two randomized controlled trials (RCT) and six non-RCT) and were included (n=60939 patients; 82% male, average age of 62±11 years). Phase 3 of a CR program showed a significant association with reduced mortality rates, with a hazard ratio (HR) of 0.56 (95% CI 0.49–0.65), with minimal evidence of statistical heterogeneity. The studies presented a range of differently structured CR programs. They varied in duration, training methods, and components.</div></div><div><h3>Conclusion</h3><div>This systematic review demonstrates that attending a phase 3 CR program has the beneficial effect of reducing mortality among patients with cardiovascular disease, in particular those with coronary artery disease. These findings highlight the importance of CR participation on a long-term basis and reinforce the value of increasing the number of specialized worldwide and optimizing patient referrals to participate in a long-term phase 3 CR program.</div></div>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 9","pages":"Pages 513-523"},"PeriodicalIF":2.0000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Portuguesa De Cardiologia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0870255126002398","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

The primary objective of this study was to assess the impact of attending a phase 3 cardiac rehabilitation (CR) program on all-cause mortality.

Methods

We conducted a systematic review using database searches (MEDLINE and Cochrane Central Register of Controlled Trials) up to December 2022 to identify studies that compared adult patients undergoing phase 3 of CR with those receiving usual care.

Results

Out of a total of 1867 identified articles, eight met the eligibility criteria (two randomized controlled trials (RCT) and six non-RCT) and were included (n=60 939 patients; 82% male, average age of 62±11 years). Phase 3 of a CR program showed a significant association with reduced mortality rates, with a hazard ratio (HR) of 0.56 (95% CI 0.49–0.65), with minimal evidence of statistical heterogeneity. The studies presented a range of differently structured CR programs. They varied in duration, training methods, and components.

Conclusion

This systematic review demonstrates that attending a phase 3 CR program has the beneficial effect of reducing mortality among patients with cardiovascular disease, in particular those with coronary artery disease. These findings highlight the importance of CR participation on a long-term basis and reinforce the value of increasing the number of specialized worldwide and optimizing patient referrals to participate in a long-term phase 3 CR program.

查看原文本刊更多论文

参加3期心脏康复的全因死亡率益处：一项系统综述。

目的：本研究的主要目的是评估参加3期心脏康复（CR）计划对全因死亡率结果的影响。方法：我们使用数据库检索（MEDLINE和Cochrane中央对照试验注册库）进行了一项系统综述，截至2022年12月，以确定将接受CR 3期和接受常规治疗的成年患者进行比较的研究。结果：在共1867篇确定的文章中，8篇符合入选标准（2项随机对照试验（RCT）和6项非RCT）并被纳入（N= 60,939例患者，82%为男性，平均年龄62±11岁）。CR项目的第3阶段显示与降低死亡率有显著关联，显示风险比（HR）为0.56 (95% CI 0.49-0.65)，统计异质性的证据最小。这些研究提出了一系列组织方式不同的社会责任项目。它们在持续时间、训练方法和组成部分上各不相同。结论：本系统综述表明，参加3期CR计划对降低心血管疾病患者，特别是冠状动脉疾病患者的死亡率有有益作用。这些发现强调了长期参与CR的重要性，并强调了在全球范围内增加专业中心数量和优化患者转诊以参与3期CR长期项目的价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Portuguesa De Cardiologia CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.70

自引率

22.20%

发文量

205

审稿时长

54 days

期刊介绍： The Portuguese Journal of Cardiology, the official journal of the Portuguese Society of Cardiology, was founded in 1982 with the aim of keeping Portuguese cardiologists informed through the publication of scientific articles on areas such as arrhythmology and electrophysiology, cardiovascular surgery, intensive care, coronary artery disease, cardiovascular imaging, hypertension, heart failure and cardiovascular prevention. The Journal is a monthly publication with high standards of quality in terms of scientific content and production. Since 1999 it has been published in English as well as Portuguese, which has widened its readership abroad. It is distributed to all members of the Portuguese Societies of Cardiology, Internal Medicine, Pneumology and Cardiothoracic Surgery, as well as to leading non-Portuguese cardiologists and to virtually all cardiology societies worldwide. It has been referred in Medline since 1987.